[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100433427":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Manitoba","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Embolization of Middle Meningeal Artery for Subdural Hematoma","EXPERIMENTAL","All patients with CSDH will undergo embolization of Middle Meningeal artery",[13],"Procedure: Embolization of the middle meningeal artery",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Embolization of the middle meningeal artery","embolization of the middle meningeal artery with an embolic agent (Microparticles, liquid embolic agents, SwiftPAC coils or others).",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Jai Shankar, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","4313734164","shivajai1@gmail.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Susan Alcock, RN","2047893669","susan.alcock@umanitoba.ca",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":20,"geoPoint":20,"contacts":43},"Health Sciences centre","RECRUITING","Winnipeg MB","Manitoba","R3A 1R9","Canada","CA",[44,47,50],{"name":45,"role":27,"phone":46,"phoneExt":20,"email":29},"Jai Shankar, MD FRCPC","431 373 4164",{"name":48,"role":27,"phone":49,"phoneExt":20,"email":33},"Susan Alcock","204 789 3996",{"name":45,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Jai Shankar","Professor","100433427","embolization-of-middle-meningeal-artery-for-subdural-hematoma-in-canada-emma-can-100433427",false,"NCT04923984","Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)","Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada -EMMA-Can","EMMA-Can","Inclusion Criteria:\n\n\\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.\n\nExclusion Criteria:\n\n* If informed consent cannot be obtained from the patient or their substitute decision maker.\n* Known allergy to liquid embolic agent","ALL","18 Years",{"count":65,"type":66},1000,"ESTIMATED","INTERVENTIONAL",[69],"NA","EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH.\n\nHypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.",[72],"Subdural Hematoma",[74,75,76],"Embolization","Middle Meningeal Artery","Chronic Subdural Hematoma","2026-02-02",{"date":79,"type":80},"2026-02-03","ACTUAL",{"date":82,"type":80},"2021-05-01",{"date":84,"type":66},"2029-12-31",{"name":5,"class":6},1]